Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design.

AIMS The combined prophylactic strategy of sodium bicarbonate plus N-acetylsyteine (NAC) seems to be effective in preventing contrast induced acute kidney injury (CI-AKI) in patients at low-to-medium risk. However, in patients at high and very high risk the rate of CI-AKI is still high. In this subset of patients the anticipated advantages of the RenalGuard(tm) System should be investigated. The RenalGuard(tm) System (PLC Medical Systems, Inc., Franklin, MA, USA) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard therapy, which is based on the theory that creating and maintaining a high urine output is beneficial by allowing a quick elimination of contrast media, and, therefore, reducing its toxic effects. METHODS AND RESULTS The REMEDIAL II trial is a randomised, multicentre, investigator-sponsored trial addressing the hypothesis that the RenalGuard System is superior to the prophylaxis with sodium bicarbonate infusion plus NAC in preventing CI-AKI in high and very high risk patients. Consecutive patients with chronic kidney disease (CKD) and at high to very high risk for CI-AKI, referred to our institutions for coronary and/or peripheral procedures, will be randomly assigned to 1) prophylactic administration of sodium bicarbonate plus NAC (control group) and 2) RenalGuard System treatment (RenalGuard group). All enrolled patients must have an estimated glomerular filtration rate ≤ 30 ml/min/1.73 m2 and/or a contrast nephropathy risk score ≥ 11. In all cases iodixanol (an iso-osmolar, non-ionic contrast agent) will be administered. The primary endpoint is an increase of ≥ 0.3 mg/dL in the serum creatinine concentration 48 hours after the procedure. CONCLUSIONS The REMEDIAL II trial will give important answers on how to prevent CI-AKI in high and very high risk patients undergoing contrast media exposure.

[1]  A. Colombo,et al.  Cystatin C and Contrast-Induced Acute Kidney Injury , 2010, Circulation.

[2]  A. Szabo,et al.  High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. , 2009, The American journal of medicine.

[3]  S. Waikar,et al.  Creatinine kinetics and the definition of acute kidney injury. , 2009, Journal of the American Society of Nephrology : JASN.

[4]  J. Plutzky,et al.  The pathologic continuum of diabetic vascular disease. , 2009, Journal of the American College of Cardiology.

[5]  C. Parikh,et al.  Urinary biomarkers for acute kidney injury: perspectives on translation. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[6]  A. Colombo,et al.  Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A Randomized Comparison of 3 Preventive Strategies , 2007, Circulation.

[7]  John A Kellum,et al.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury , 2007, Critical care.

[8]  J. Bonventre.  Diagnosis of acute kidney injury: from classic parameters to new biomarkers. , 2007, Contributions to nephrology.

[9]  P. Aspelin,et al.  Contrast-Induced Nephropathy: A Clinical and Evidence-Based Approach , 2006, Circulation.

[10]  R. O’Neill,et al.  Multicentre trials: a US regulatory perspective , 2005, Statistical methods in medical research.

[11]  R. Bellomo,et al.  The 3rd International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) , 2005, The International journal of artificial organs.

[12]  G. Stone,et al.  A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. , 2004, Journal of the American College of Cardiology.

[13]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[14]  R. Bersin,et al.  Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. , 2004, JAMA.

[15]  A. Colombo,et al.  Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. , 2004, European heart journal.

[16]  G. Marenzi,et al.  The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. , 2003, The New England journal of medicine.

[17]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  S. Eckstein.  Ethical principles for medical research involving human subjects. , 2001, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[19]  W Zidek,et al.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. , 2000, The New England journal of medicine.

[20]  W. O’Neill,et al.  A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy ☆: Results of the P.R.I.N.C.E. study , 1999 .

[21]  J. D'Elia,et al.  Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. , 1994, The New England journal of medicine.

[22]  M. Brezis,et al.  Potential deleterious effect of furosemide in radiocontrast nephropathy. , 1992, Nephron.